



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 1, 2025

Jeffrey Frelick
Chief Executive Officer
Bone Biologics Corp
2 Burlington Woods Drive, Suite 100
Burlington, MA 01803

Re: Bone Biologics Corp
Registration Statement on Form S-3
Filed June 24, 2025
File No. 333-288290

Dear Jeffrey Frelick:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Nicholas O'Leary at 202-551-4451 with any questions.

Sincerely,

Division of Corporation Finance
Office of Industrial Applications and
Services

cc: Alexander R. McClean, Esq.